Sunshine Biopharma- Warrants (15/02/2027) Accounts Payable

As of the most recent data (June 2026), SBFMW shows a accounts payable of $4.9M. That compares with $4.8M in the prior-year period — up 1.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SBFMW's accounts payable is now $4.9M (was $4.8M) — a 1.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Sunshine Biopharma- Warrants (15/02/2027) is outperforming or lagging.

Tracking SBFMW's accounts payable over time shows whether Sunshine Biopharma- Warrants (15/02/2027) is scaling, shrinking, or reshaping that part of the business. The current reading is $4.9M That compares with $4.8M in the prior-year period — up 1.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Sunshine Biopharma- Warrants (15/02/2027)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $4.9M) with ownership activity and broader fundamentals.

Sunshine Biopharma- Warrants (15/02/2027)'s accounts payable is $4.9M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.